InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently commented on NSPR. Piper Sandler reaffirmed an "overweight" rating and issued a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th. Lake Street Capital started coverage on InspireMD in a research note on Wednesday, December 11th. They set a "buy" rating and a $5.00 price objective for the company.

InspireMD Trading Up 0.7 %

NYSE:NSPR traded up $0.02 during trading hours on Friday, reaching $3.00. The company had a trading volume of 11,266 shares, compared to its average volume of 29,298. The firm has a market cap of $78.25 million, a price-to-earnings ratio of -4.00 and a beta of 0.98. The firm's 50 day moving average price is $2.69 and its 200-day moving average price is $2.69. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42.

InspireMD (NYSE:NSPR - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. On average, analysts forecast that InspireMD will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 104,081 shares of the company's stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 44.78% of the company's stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.